Quarterly report pursuant to Section 13 or 15(d)

Reverse Recapitalization - Consummation of the merger (Details)

v3.22.2.2
Reverse Recapitalization - Consummation of the merger (Details) - shares
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
Business Acquisition [Line Items]      
Total shares of common stock immediately after Merger   67,641,314 58,510,550
Merger agreement      
Business Acquisition [Line Items]      
Common stock, outstanding prior to Merger 552,412    
Less: redemption of BRPA shares (216)    
Common stock of BRPA 552,196    
BRPA Founder and private shares, net of forfeited shares of 875,216 1,260,284    
Shares issued in PIPE Financing 1,000,000    
Shares issued for services 200,000    
Shares issued pursuant to conversion of Public and Private Rights 717,250    
Merger and PIPE Financing shares - common stock 3,729,730    
NeuroRx shares - common stock (1) 44,873,855    
Total shares of common stock immediately after Merger 48,603,585    
Number of shares forfeited 875,216    
Merger agreement | Stockholders of NeuroRx      
Business Acquisition [Line Items]      
Common stock outstanding upon conversion prior to Merger 14,200,586